
FDA Approves Updated Label For UNLOXCYT™ In Advanced Cutaneous Squamous Cell Carcinoma, Validating Long-Term Efficacy And Safet
New Delhi: FDA has approved an updated label for UNLOXCYT™ (cosibelimab-ipdl), incorporating longer-term follow-up data that demonstrated improved clinical outcomes in advanced cutaneous














